ACC announces late-breaking clinical trials for annual scientific session
The American College of Cardiology (ACC) announced the late-breaking clinical trials sessions for its 65th annual scientific session. The conference is taking place from April 2 to 4 at the McCormick Place convention center in Chicago.
Here are the late-breaking trials (all times are Central time):
April 2 in North Hall B1
9:05 a.m. – “Transcatheter Aortic Valve Replacement Compared with Surgery in Intermediate Risk Patients with Aortic Stenosis: Final Results from the Randomized Placement of Aortic Transcatheter Valves 2 Study.” – lead researcher Martin B. Leon, MD
9:27 a.m. – “Blood Pressure Lowering in People at Moderate Risk. The HOPE-3 Trial.” – lead researcher Eva M. Lonn, MD
9:37 a.m. – “Effects of Combined Lipid and BP-Lowering on Cardiovascular Disease in a Moderate Risk Global Primary Prevention Population.” – lead researcher Salim Yusuf, MD
April 3 in North Hall B1
8:00 a.m. – “Impact of the Cholesteryl Ester Transfer Protein Inhibitor Evacetrapib on Cardiovascular Events: Results of the ACCELERATE trial.” – lead researcher Stephen J. Nicholls, MD
8:15 a.m. – “Comparison of PCSK9 Inhibitor Evolocumab Versus Ezetimibe in Statin-intolerant Patients: The Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects 3 (GAUSS-3) Trial.” – lead researcher Steven E. Nissen, MD
8:30 a.m. – “Low-density Lipoprotein Cholesterol, Familial Hypercholesterolemia Mutation Status and Risk for Coronary Artery Disease.” – lead researcher Amit V. Khera, MD
8:45 a.m. – “Reproducible Impact of a Global Mobile Health (mHealth) Mass-Participation Physical Activity Intervention on Step Count, Sitting Behavior and Weight: the Stepathlon Cardiovascular Health Study.” – lead researcher Anand Ganesan, MD
9:00 a.m. – “Involving Patients with Low Risk Chest Pain in Discharge Decisions: A Multicenter Trial.” – lead researcher Erik P. Hess, MD
10:45 a.m. – “The Third DANish Study of Optimal Acute Treatment of Patients with ST-segment Elevation Myocardial Infarction: DEFERred stent implantation in connection with primary PCI.” – lead researcher Henning Kelbaek, MD
11:00 a.m. – “The Third DANish Study of Optimal Acute Treatment of Patients with ST-segment Elevation Myocardial Infarction: iPOSTconditioning during primary PCI.” – lead researcher Thomas Engstrom, MD
11:15 a.m. – “Effect Of Early Administration Of Intravenous Beta Blockers In Patients With ST-elevation Myocardial Infarction Before Primary Percutaneous Coronary Intervention. The Early-BAMI trial.” – lead researcher Vincent Roolvink, MD
11:30 a.m. – “Sapien 3 Transcatheter Aortic Valve Replacement versus Surgery in Intermediate-Risk Patients with Severe Aortic Stenosis: A Propensity-Matched Comparison of One-Year Outcomes.” – lead researcher Vinod H. Thourani, MD
11:45 a.m. – “Relationship Between Procedure Volume and Outcome for Transcatheter Aortic Valve Replacement in U.S. Clinical Practice: Insights from the STS/ACC TVT Registry.” – lead researcher John D. Carroll, MD
April 4 in North Hall B1
8:00 a.m. – “Antiarrhythmic Drugs for Shock-Refractory Out-of-Hospital Cardiac Arrest: The Resuscitation Outcomes Consortium Amiodarone, Lidocaine or Placebo Study.” – lead researcher Peter J. Kudenchuk, MD
8:15 a.m. – “Largest Randomized Trial Demonstrates an Effective Ablation of Atrial Fibrillation: the FIRE AND ICE Trial (NCT01490814).” – lead researcher Karl-Heinz Kuck, MD
8:30 a.m. – “A Randomized Trial of Rate Control Versus Rhythm Control for Atrial Fibrillation after Cardiac Surgery.” – lead researcher A. Marc Gillinov, MD
8:45 a.m. – “The Losmapimod To Inhibit P38 MAP Kinase As A Therapeutic Target And Modify Outcomes After An Acute Coronary Syndrome (LATITUDE-TIMI 60) Trial: Primary Results Of Part A.” – lead researcher Michelle L. O’Donoghue, MD
9:00 a.m. – “CMX-2043 for Prevention of Contrast Induced Acute Kidney Injury: The Primary Results of the CARIN Trial.” – lead researcher Deepak L. Bhatt, MD
10:45 a.m. – “Direct Renin-inhibition With Aliskiren Alone And In Combination With Enalapril, Compared With Enalapril, In Heart Failure (the ATMOSPHERE Trial).” – lead researcher John J.V. McMurray, MD
11:00 a.m. – “Effect of Ularitide on Short- and Long-Term Clinical Course of Patients with Acutely Decompensated Heart Failure: Primary Results of the TRUE-AHF Trial.” – lead researcher Milton Packer, MD
11:15 a.m. – “The Final Results of the IxCell-DCM Trial: Transendocardial Injection of Ixmyelocel-T in Patients with Ischemic Dilated Cardiomyopathy.” – lead researcher Timothy D. Henry, MD
11:30 a.m. – “The Effect of Vagal Nerve Stimulation in Heart Failure: Primary Results of the INcrease Of VAgal TonE in chronic Heart Failure (INOVATE-HF) Trial.” – lead researcher Michael Robert Gold, MD
11:45 a.m. – “Non-invasive Lung IMPEDANCE-Guided Preemptive Treatment in Chronic Heart Failure Patients: a Randomized Controlled Trial (IMPEDANCE-HF trial).” – lead researcher Michael Shochat, MD
Executive Editor
Tim Casey joined TriMed Media Group in 2015 as Executive Editor. For the previous four years, he worked as an editor and writer for HMP Communications, primarily focused on covering managed care issues and reporting from medical and health care conferences. He was also a staff reporter at the Sacramento Bee for more than four years covering professional, college and high school sports. He earned his undergraduate degree in psychology from the University of Notre Dame and his MBA degree from Georgetown University.